Arrowhead RNAi drug lowers Alzheimer's protein in early study

· Health · United States

Arrowhead Pharmaceuticals reported early-stage results showing that an RNA interference medicine given as a subcutaneous injection appeared to cross into the brain and lower levels of tau, a protein implicated in Alzheimer's disease. The finding, described as a first for a subcutaneously administered RNAi therapy, suggests the company's delivery approach can reach the central nervous system, which has long been a barrier for large-molecule and genetic medicines. The data are early and come from a small study, so they do not yet establish whether lowering tau changes clinical outcomes for patients. Still, the result drew attention because Alzheimer's drug development has been dominated by antibodies targeting amyloid, and a scalable, injectable approach could open a different route to treating the disease if later trials confirm the effect.

Why it matters：If subcutaneous RNAi can reliably reach the brain, it widens the delivery options for neurological disease and shifts competition away from infusion-based antibodies and toward genetic medicines.

Key points

  • The drug is administered as a subcutaneous injection, unlike typical CNS therapies.
  • It targets tau, a protein implicated in Alzheimer's disease.
  • The results come from an early-stage study and have not yet shown clinical benefit.

Sources (original reporting)

More stories from this day